Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H1 2018
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.
It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 4 and 2 respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Metabolic Disorders which include indications Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Gastric Cancer, Melanoma, Myocardial Infarction, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Advanced Malignancy, Angina (Angina Pectoris), Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Nasopharyngeal Cancer, Parkinson's Disease, Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Thromboangiitis obliterans (Buerger disease).
The latest report Hepatocyte Growth Factor - Pipeline Review, H1 2018, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook